Page 33 - ARNM-3-1

Advances in Radiotherapy
& Nuclear Medicine Chinese Expert Consensus for LACC

Funding analysis of the WHO Global Cervical Cancer Elimination
Initiative. Lancet Glob Health. 2023;11(2):e197-e206.
This consensus was supported by the Key Specialization
Project of Beijing Natural Science Foundation (Grant No. doi: 10.1016/S2214-109X(22)00501-0
Z2008), the Clinical Scientist Training Program at Peking 4. Monk BJ, Tan DSP, Hernandez Chagui JD, et al. Proportions
University (Grant No. BMU2023PYJH009), Clinical Key and incidence of locally advanced cervical cancer:
Project Innovation Project Class A at the Third Hospital of A global systematic literature review. Int J Gynecol Cancer.
Peking University (Grant No. BYSYZD2021011), and the 2022;32(12):1531-1539.
National Clinical Key Specialization Construction Project doi: 10.1136/ijgc-2022-003801
Special Fund (2021).
5. Liu H, Ma X, Sun C, et al. Concurrent chemoradiotherapy
Conflict of interest followed by adjuvant chemotherapy versus concurrent
chemoradiotherapy alone in locally advanced cervical
Junjie Wang is the Editor-in-Chief and Ping Jiang is cancer: A systematic review and meta-analysis. Front Oncol.
the Editorial Board Member of this journal, but was 2022;12:997030.
not in any way nvolved in the editorial and peer-review doi: 10.3389/fonc.2022.997030
process conducted for this paper, directly or indirectly.
Separately, other authors declared that they have 6. Gustafson DH, Shukla RK, Delbecq A, Walster GW.
A comparative study of differences in subjective likelihood
no known competing financial interests or personal estimates made by individuals, interacting groups, Delphi
relationships that could have influenced the work groups, and nominal groups. Organ Behav Hum Perform.
reported in this paper. 1973;9(2):280-291.
Author contributions doi: 10.1016/0030-5073(73)90052-4

Conceptualization: Junjie Wang, Ping Jiang, Zi Liu, Yunyan 7. Gallego D, Bueno S. Exploring the application of the
Delphi method as a forecasting tool in information systems
Zhang and technologies research. Technol Anal Strateg Manag.
Writing–original draft: Ping Jiang, Zhuhui Yuan 2014;26(9):987-999.
Writing–reviewing & editing: All authors
doi: 10.1080/09537325.2014.941348
Ethics approval and consent to participate 8. Schefter T, Winter K, Kwon JS, et al. RTOG 0417: Efficacy
Not applicable. of bevacizumab in combination with definitive radiation
therapy and cisplatin chemotherapy in untreated patients
Consent for publication with locally advanced cervical carcinoma. Int J Radiat Oncol
Biol Phys. 2014;88(1):101-105.
Not applicable.
doi: 10.1016/j.ijrobp.2013.10.022
Availability of data 9. Lu H, Wu Y, Liu X, et al. Endostar, an antiangiogenesis

Data for this study can be obtained from the cited original inhibitor, combined with chemoradiotherapy for locally
advanced cervical cancer. Oncol Res. 2022;28(9):929-944.
articles.
doi: 10.3727/096504021X16318716607908
References
10. Shu H, Dong Y, Xu Z, et al. The efficacy and safety of
1. National Cancer C, Cervical Cancer Expert Committee of continuous intravenous endostar treatment combined with
National Cancer Quality Control C. Quality control index concurrent chemoradiotherapy in patients with locally
for standardized diagnosis and treatment of cervical cancer advanced cervical squamous cell carcinoma: A randomized
in China (2022 edition). Zhonghua Zhong Liu Za Zhi. controlled trial. Front Oncol. 2021;11:723193.
2022;44(7):615-622.
doi: 10.3389/fonc.2021.723193
doi: 10.3760/cma.j.cn112152-20220511-00328
11. De la Rochefordiere A, Kamal M, Floquet A, et al. PIK3CA
2. Erratum: Global cancer statistics 2018: GLOBOCAN pathway mutations predictive of poor response following
estimates of incidence and mortality worldwide standard radiochemotherapy ± cetuximab in cervical cancer
for 36 cancers in 185 countries. CA Cancer J Clin. patients. Clin Cancer Res. 2015;21(11):2530-2537.
2020;70(4):313.
doi: 10.1158/1078-0432.CCR-14-2368
doi: 10.3322/caac.21609
12. Fracasso PM, Duska LR, Thaker PH, et al. An exploratory
3. Singh D, Vignat J, Lorenzoni V, et al. Global estimates of study of neoadjuvant cetuximab followed by cetuximab and
incidence and mortality of cervical cancer in 2020: A baseline chemoradiotherapy in women with newly diagnosed locally

Volume 3 Issue 1 (2025) 25 doi: 10.36922/arnm.4032